Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C
Ozeki, I.; Karino, Y.; Toyota, J.
Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 4): 267-274
2011
ISSN/ISBN: 0047-1852 PMID: 22096930 Document Number: 654437
Document emailed within 1 workday
Related Documents
Garg, V.; van Heeswijk, R.; Yang, Y.; Kauffman, R.; Smith, F.; Adda, N. 2012: The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir Journal of Clinical Pharmacology 52(10): 1574-1583Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Fernández-Crehuet, P.; Ruiz-Villaverde, R. 2018: DRESS syndrome induced by telaprevir: a potentially fatal adverse event in chronic hepatitis C therapy Cutis 102(5): E4-E6
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Nigro, L.; Romano, F.; Tosto, S.; Zagami, A.; Bruno, S.; Nunnari, A. 1999: Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor Italian Journal of Gastroenterology and Hepatology 31(1): 85-86
Macías, J.; Mira, J.é A.; López-Cortés, L.F.; Santos, I.; Girón-González, J.é A.; González-Serrano, M.; Merino, D.; Hernández-Quero, J.é; Rivero, A.; Merchante, N.ás.; Trastoy, M.ón.; Carrillo-Gómez, R.; Arizcorreta-Yarza, A.; Gómez-Mateos, J.ús.; Pineda, J.A. 2006: Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C Antiviral Therapy 11(7): 839-846
Lin, W.H.; Feng, H.-P.; Shadle, C.R.; O'Reilly, T.; Wagner, J.A.; Butterton, J.R. 2014: Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone European Journal of Clinical Pharmacology 70(9): 1107-1113
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Sabo, J.P.; Lang, B.; Elgadi, M.; Huang, F. 2015: Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers Antimicrobial Agents and ChemoTherapy 59(1): 514-519
Armignacco, O.; Andreoni, M.; Sagnelli, E.; Puoti, M.; Bruno, R.; Gaeta, G.Battista.; Perno, C.F.; Santantonio, T.A.; Bonfanti, P.; Bonora, S.; Borderi, M.; Castagna, A.; d'Arminio Monforte, A.; De Luca, A.; Grossi, P.; Guaraldi, G.; Maggiolo, F.; Mussini, C.; Sagnelli, C.; Tavio, M.; Torti, C.; Uberti-Foppa, C.; Andreoni, M.; Angarano, G.; Antinori, A.; Armignacco, O.; Carosi, G.; Chirianni, A.; Di Perri, G.; Galli, M.; Lazzarin, A.; Rizzardini, G.; Sagnelli, E.; Taliani, G. 2014: Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease new microbiologica 37(4): 423-438
Iyoda, K.; Kato, M. 2004: Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 62 Suppl 7(Part 1): 502-505
Piroth, L.; Grappin, M.; Waldner, A.; Sgro, C.; Duong, M.; Buisson, M.; Chavanet, P.; Portier, H. 1999: Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients Presse Medicale 28(8): 381-387
Pol, S. 2002: Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance Gastroenterologie Clinique et Biologique 26(Special Issue 2): B264-B273
Knobel, H.; Goday, A.; Grau, S. 1998: Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients Medicina Clinica 111(15): 599
Bruno, C.M.; Valenti, M.; Bertino, G.; Ardiri, A.; Consolo, M.; Mazzarino, C.M.; Amoroso, A.; Neri, S. 2009: Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features Panminerva Medica 51(4): 191-196
Flisiak, R.; Maxwell, P.; Prokopowicz, D.; Timms, P.M.; Panasiuk, A. 2002: Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis Hepato-Gastroenterology 49(47): 1369-1372
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Yu, J.; Liu, B.-w.; Lan, L.; Yuan, Y.; Zhang, H.; Jia, C.-h. 2010: Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(5): 373-375
Ma, L.-n.; Chen, X.-y.; Chen, J.; Shen, C.-l.; Wang, J.-t. 2006: Efficacy, influencing factors and safety of PEG-INF alpha-2a (PEG-INF-2a) in the treatment of chronic hepatitis C: analysis of 89 patients Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 20(2): 42-45